He speculates that it could also cut the disease's rate of progression in half, extending life by as much as a decade and being a necessary treatment for anyone at risk for the disease.
But even in this short paragraph, the hematologist moves rapidly from response rate percentages to progression percentages in the former, high numbers being good, in the latter, high numbers being bad.
Celldex CEO Anthony Marucci has said previously that a meaningful and positive response rate in the study would be 12% to 15% with a progression-free survival of greater than 12 weeks.